Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Ploni who wrote (3155)	3/28/1998 11:15:00 PM
From: Dauntless	Read Replies (3) \| Respond to of 7041

Peter & Charles - Zonagen revenues. Zonagen received $10 up front from SGP as part of the deal for distribution rights to Vasomax. There is another $37 million in milestone payments included in the deal. If it takes Zonagen 3 years to reach all the milestones then it is about $12 million/year. We'll know this week from the 10K exactly how much interest income there was in '97 & get a good idea about '98. There is also a possibility of some revenue in '98 from Latin American sales of Vasomax - and definitely some in '99.